Drug intelligence / Profile preview

etc-1001

Development stage: Unknown
Lead developer: Esperion Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ETC-1001 is an oral small molecule drug candidate being investigated for the treatment of hypercholesterolemia and other cardiometabolic disorders. In Phase 2 clinical trials, it demonstrated significant LDL-C lowering effects of up to 43% in patients with Type 2 diabetes and hypercholesterolemia. The drug was also associated with improvements in other cardiometabolic risk factors, including reductions in non-HDL-C, high-sensitivity C-reactive protein (hsCRP), and blood pressure in patients with hypertension. ETC-1001 showed a favorable tolerability profile with no reported cases of myalgia in clinical trials.

Other names: 1,13-dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

Targets

ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on etc-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etc-1001.

Explore the full profile